Sponsor Study ID:
A Randomized, Phase 3, Double Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High risk, Locally Advanced Cervical Cancer (KEYNOTE A18 / ENGOT cx11)
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.
(MUSC NetID required for document access)
For more information about the trial above please contact the study team: